J. Fairchild

发表

CheckMate 451: A randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC).

R. Govindan, P. Postmus, S. Peters, 2016 .

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Christopher R. Cabanski, Vanessa M. Hubbard-Lucey, E. Wherry, 2022, Nature Medicine.

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.

Christopher R. Cabanski, Lacey J. Kitch, Vanessa M. Hubbard-Lucey, 2021, The Lancet. Oncology.

Biomarker Analyses in Phase 2 Single-Agent Trials of Dasatinib for Breast Cancer.

L. Ploughman, D. Brickman, C. Harbison, 2009 .

Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.

P. Ascierto, P. Ott, M. Hellmann, 2017 .

Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.

N. Ibrahim, J. Sparano, R. Finn, 2009 .

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study.

R. Govindan, Keunchil Park, S. Peters, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

N. Ibrahim, J. Sparano, R. Finn, 2011, Clinical Cancer Research.

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

M. Hellmann, V. Moreno, J. Eder, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Michael Thomas, Yi-long Wu, E. Felip, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.

S. Gettinger, S. Peters, T. Ciuleanu, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC).

C. Logothetis, Y. Loriot, T. Beer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).

S. Gettinger, S. Peters, D. Spigel, 2016 .

Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.

F. Hodi, S. Kummar, D. Khalil, 2024, The Journal of experimental medicine.